Publications Database

Campbell M. et al. (1971)

Imipramine in preschool autistic and schizophrenic children.

Journal of Autism and Developmental Disorders

1(3), pp. 267-282.

Read Abstract (New Window)

Campbell M. et al. (1976)

Levodopa and levoamphetamine: a crossover study in young schizophrenic children.

Current Therapeutic Research

19(1), pp. 70-86

Campbell M. et al. (1990)

Naltrexone in autistic children: a double-blind and placebo-controlled study.

Psychopharmacology Bulletin

26(1), pp. 130-135

Read Abstract (New Window)

Campbell M. et al. (1989)

Naltrexone in autistic children: an acute open dose range tolerance trial.

Journal of the American Academy of Child and Adolescent Psychiatry

28(2), pp. 200-206

Read Abstract (New Window)

Campbell M. et al. (1993)

Naltrexone in autistic children: behavioral symptoms and attentional learning.

Journal of the American Academy of Child and Adolescent Psychiatry

32(6), pp. 1283-1291

Read Abstract (New Window)

Campbell M. (1998)

Naltrexone in infantile autism.

Psychopharmacology Bulletin

24(1), pp. 135-139

Campbell M. (1975)

Pharmacotherapy in early infantile autism.

Biological Psychiatry

10(4), pp. 399-423

Read Abstract (New Window)

Campbell M. , Cueva J. E. (1995)

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years: Part 1

Journal of the American Academy of Child and Adolescent Psychiatry

34(9), pp. 1124-1132

Read Abstract (New Window)

Campbell M. et al. (1972)

Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children.

Journal of Autism and Developmental Disorders

2(4),

Read Abstract (New Window)

Campbell M. et al. (1986)

Short-term efficacy and safety of fenfluramine in hospitalized preschool-age autistic children: an open study.

Psychopharmacology Bulletin

22(1), pp. 141-147

Campbell M. et al. (1990)

Stereotypies and tardive dyskinesia: abnormal movements in autistic children.

Psychopharmacology Bulletin

26(2), pp. 260-266

Read Abstract (New Window)

Campbell M. et al. (1982)

The effects of haloperidol on learning and behavior in autistic children.

Journal of Autism and Developmental Disorders

12(2), pp. 167-175

Read Abstract (New Window)

Ernst M. et al. (1993)

Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.

Psychopharmacology Bulletin

29(2), pp. 221-227

Read Abstract (New Window)

Gonzalez N. M. et al. (1994)

Naltrexone plasma levels, clinical response and effect on weight in autistic children.

Psychopharmacology Bulletin

30(2), pp. 203-208

Read Abstract (New Window)

Locascio J. et al. (1991)

Factors related to haloperidol response and dyskinesias in autistic children.

Psychopharmacology Bulletin

27(2), pp. 119-126

Malone R. P. et al. (1991)

Repeated episodes of neuroleptic-related dyskinesias in autistic children.

Psychopharmacology Bulletin

27(2), pp. 113-117

Read Abstract (New Window)

Perry R. et al. (1989)

Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration.

Journal of the American Academy of Child and Adolescent Psychiatry

28 pp. 87-92

Read Abstract (New Window)

Sanchez L. e. et al. (1995)

A comparison of live and videotape ratings: clomipramine and haloperidol in autism.

Psychopharmacology Bulletin

31(2), pp. 371-378.

Read Abstract (New Window)

Sanchez L. e. et al. (1996)

A pilot study of clomipramine in young autistic children.

Journal of the American Academy of Child and Adolescent Psychiatry

35(4), pp. 537-544

Read Abstract (New Window)

Silva R. R. et al. (1993)

Haloperidol withdrawal and weight changes in autistic children.

Psychopharmacology Bulletin

29(2), pp. 287-291

Read Abstract (New Window)